Browse drugs

…city, with G3/4 events reported in 22% compared with 14% in the nivolumab monotherapy arm. An update presented at the European Society of…

…state health sector in which several novel cancer drugs such as osimertinib, alectinib and immunotherapy are not approved for use in advanc…

…ously evaluated in patients with advanced melanoma treated with nivolumab plus ipilimumab. This analysis compared TFS for nivolumab plus …

…, nivolumab-(n=15), and nivolumab+relatlimab (n=14) followed by nivolumab+relatlimab in first-line advanced melanoma. Overall primary obj…

…up, with overall survival ranging from 48.8 to 85.4 months from nivolumab initiation. Of the six patients who resumed treatment, only one…

…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …

…Background and Importance Nivolumab was the first anti-PD-1 drug to be marketed, marking a signific…

…t saving of €11,000 per patient when using Nivolumab instead of Pembrolizumab, with equivalent efficacy. This finding supports a review of pr…

… of nivolumab SC 720 mg or 960 mg±rHuPH20 2000 U/mL followed by nivolumab intravenous (IV) 480 mg every 4 weeks (Q4W). Patients receiving…

…rolled in a first-line phase II trial of the anti-PD-1 antibody nivolumab.13 Together, these data suggest then an immunologically enriche…

…minantly stereotactic radiosurgery (SRS)) followed by continued osimertinib, with encouraging PFS/OS and acceptable toxicity. By contrast, …

…comes, and overall survival (OS) in NSCLC patients treated with nivolumab.Methods This observational, multicenter, prospective study enro…